Isomorphic Labs, the AI drug discovery company founded by Demis Hassabis, has raised $5 billion in a Series C funding round, highlighting growing investor confidence in artificial intelligence’s potential to transform pharmaceutical research.
The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet, Google’s parent company. Isomorphic said the funding will support the design and development of new medicines using AI.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
Hassabis Focuses On The Next Phase Of Isomorphic Labs
The fundraising comes three and a half months after Hassabis stepped back as CEO of Google DeepMind, the AI research lab he co-founded before its acquisition by Google in 2014. He has led Isomorphic Labs since it spun out of DeepMind in 2021.
“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” Hassabis said.
He added that the new capital would help the company develop foundational biology models, deepen its understanding of systemic disease and advance its first therapeutic programmes towards clinical trials.
AI Drug Discovery Attracts Growing Investment
Isomorphic is developing a proprietary drug-design engine alongside a pipeline of potential therapies designed using AI. The company aims to apply these tools to the development of a new generation of medicines.
It is entering a market that is attracting increasing attention from technology companies and investors. Anthropic announced an AI drug discovery programme in June, while OpenAI partnered with Novo Nordisk in April to explore the technology’s applications in drug development.
Drug discovery startups raised a record $23.2 billion in 2026, according to deal-tracking platform Dealroom.
Isomorphic’s latest funding follows a $2.1 billion Series B round announced in May, bringing the company’s fundraising into focus as investment in AI-driven pharmaceutical research continues to grow.







